论文部分内容阅读
癫痫(EP)患者在服用苯巴比妥、苯妥英钠、扑痫酮时可产生轻微的骨软化状态(抗惊厥药骨软化病,但能用VitD_2治疗纠正,而单服卡马西平治疗的EP患者则不产生钙和VitD代谢物的病理生理改变。故可用于研究EP患者的VitD_2和D_3代谢产物的差异。作者研究30例用卡马西平治疗的EP患者,其中女16例,男11例,年龄20～68岁(平均40岁),用卡马西平治疗1～10年(平均4年),卡马西平血清浓度在3～11mg/L(平均7mg/L)。用双盲法分为两组:D_2治疗组和D_3治疗组,每天4000 IU,共24周。分别测定治疗前(to),治疗后3周(t_3)及治疗后24周(t_(24))血清中VitD代谢物的浓度。结果发现D_2治疗组在t_3和t_(24)250HD_2浓度明显增加,而T_(24)250HD_3明显减少,24,25(OH)_2D_3和
Epilepsy (EP) patients in the use of phenobarbital, phenytoin sodium, epilepsy ketone can produce a slight osteomalacia (anticonvulsant osteomalacia, but can be used to correct VitD_2 treatment, while the single-shot carbamazepine treatment EP Patients do not produce the pathophysiological changes of calcium and VitD metabolites.Therefore, they can be used to study the differences of VitD_2 and D_3 metabolites in patients with EP.The author studied 30 patients with EP treated with carbamazepine, including 16 females and 11 males , Aged 20 to 68 years old (average 40 years), treated with carbamazepine for 1 to 10 years (average 4 years), and carbamazepine serum concentration of 3 to 11 mg / L (mean 7 mg / L) Were divided into two groups: D_2 treatment group and D_3 treatment group, with 4000 IU daily for 24 weeks.The levels of VitD in serum before treatment, 3 weeks after treatment (t_3) and 24 weeks after treatment (t_ (24) The results showed that the concentrations of T_ (24) 250HD_3 and T_ (24) 250HD_3 in D_2 treatment group were significantly increased at t_3 and t_ (24) 250HD_2, 24 and 25 (OH) _2D_3 and